Cultural Description vs Clinical Endorsement
Describing how a people use a plant is not the same as showing it works or is safe, and a single isolated compound in a clinic is not the same as the tradition it came from.
Content last updated . This page has not been medically reviewed.
When this library describes a tradition, it is describing a culture, not recommending a treatment. A long history of use is a real part of human history. It is not a test of whether something is safe or effective for a medical purpose. This page explains the difference and how to read both kinds of claims. It gives no advice on use.
Evidence labels used here
We use the library's usual labels in plain terms. Established means supported by strong, repeated human studies. Promising but limited means early human results with important gaps. Insufficient evidence means too little to say. Marketing claim means a statement made to sell something, not a research result. Proper evidence not found means we looked and did not find usable sources. A tradition's own account of meaning and healing is neither of these. It is a cultural description, and we say so.
Three different kinds of statement
| Kind of statement | What it can tell you | What it cannot tell you |
|---|---|---|
| Cultural description (how a people use a plant, and why) | Meaning, history, social role, rules around use | Whether a clinical outcome is caused by the substance |
| Clinical research (trials of a defined product) | Effects and harms in a specific group, under study conditions | Whether a traditional practice works, or whether results apply to other forms |
| Marketing | What a seller wants you to believe | Anything reliable |
Historical use is not demonstrated effectiveness
The U.S. National Institute on Drug Abuse says psychedelic and dissociative drugs are derived from plants and fungi with a long history of use in many cultures, and that researchers are now exploring their use in medical settings, for example for substance use disorders.[1] "Exploring" is the key word. That page also says poor mental health outcomes may be more likely outside of clinical use.[1] A narrative review of several natural psychoactive substances for substance use disorders concluded that observational research and preliminary clinical studies indicate "therapeutic potential and relative safety" in appropriate contexts, and also that more interdisciplinary research is necessary.[2] On our evidence labels, that reads as promising but limited at best, and it is a review of the field, not a verdict on any one tradition.
An isolated compound is not the cultural practice
A tradition usually includes the plants, the people who guide, the setting, teachings and obligations. A clinical trial typically tests one defined product in a defined setting. The Chacruna Institute article on patents shows how the two can separate: it describes patent claims on formulations that combine DMT with plant alkaloids to copy the "ayahuasca effect", without claiming the traditional plants.[3] Those products are not the tradition, and a trial on one of them says nothing about a ceremony. The reverse also holds. A ceremony cannot be used as evidence for a product. See Traditional Preparations vs Isolated Compounds and Clinical Formulations vs Nonmedical Products.
A case where the gap is serious: iboga and ibogaine
Iboga has deep roots in Bwiti practice in Gabon.[4] The Chacruna Institute article also says that, unlike classic psychedelics, ibogaine is more dangerous, and that higher doses or pre-existing cardiovascular problems can lead to overdose, paralysis and death.[4] Cultural importance and cardiac risk are both true, and neither cancels the other. See Iboga and Ibogaine.
What Indigenous scholars and communities say
A 2026 commentary in the Journal of Psychopharmacology argues that Indigenous methodologies, including ritual, community-based practices and ecological approaches, offer insights relevant to both safety and efficacy, and that research should embed free, prior and informed consent and benefit-sharing.[5] This is the authors' argument, not a trial result. A separate review describes ritual use of natural psychoactive substances as "elaborate technologies" for navigating altered states, and describes a pilot intercultural program run by the Yaqui tribe in Sonora, Mexico.[2] We did not find outcome data from that program in the abstract we read. Proper evidence not found here for outcomes.
How to read a claim
- Who is speaking? A community member, a scholar, a clinician or a seller?
- What exactly is claimed? A cultural meaning, a historical fact or a health outcome?
- What is the substance? A whole plant or brew, one compound, or a lab product?
- What is the evidence? A story, an observation, or a controlled trial?
- Who benefits? Check whether a product or service is being sold.
See Cultural Context and Respectful Representation of Traditions and Historical Use vs Clinical Evidence in Traditional Medicine.
Safety note
Do not use this page, or any tradition's description, as a reason to start or stop any medicine or substance. Many psychoactive plants affect the heart, mood and other medicines. Talk with a prescriber or clinician. In the United States, call 911 for an emergency and 988 for a suicide or mental health crisis.
Frequently asked questions
Does a long tradition prove a plant is safe?
No. A history of use shows a cultural practice, not a safety record. Iboga and ibogaine show that cultural importance and medical risk can both be real.[4]
Is a traditional ceremony the same as clinical therapy?
No. Clinical research tests defined products under study conditions, while traditions include teachings, guides and obligations that are not trial products.[2]
Do clinical trials validate the traditions?
No. A trial can speak only to the product and setting it tested.[3]
Can Indigenous knowledge inform science?
Scholars argue that it can, if consent, benefit-sharing and Indigenous leadership are built in.[5]
References
- National Institute on Drug Abuse (NIDA). Psychedelic and Dissociative Drugs, research topic page. Psychedelic and Dissociative Drugs (National Institute on Drug Abuse). Read 2026-10-22.
- Journal of Studies on Alcohol and Drugs, 2024 (narrative review), PMID 39400118. Traditional Medicine, Culture, and Psychedelic Science: New Pathways for Recovery From Substance Use Disorders. J Stud Alcohol Drugs 2024. Read 2026-10-22.
- Leite M, Espinoza Cárcamo P. Chacruna Institute, 20 May 2026. Not Many Patents Threaten Traditional Knowledge About Ayahuasca (Chacruna Institute, 20 May 2026). Read 2026-10-22.
- Ermakova A. Iboga Conservation. Chacruna Institute, 7 June 2021. Iboga Conservation (Chacruna Institute, 7 June 2021). Read 2026-10-22.
- Journal of Psychopharmacology, 2026 (commentary), PMID 41618525. Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration. J Psychopharmacol 2026. Read 2026-10-22.